Distinguished in Lung Nodules

Dr. Justin F. Gainor

Oncology | Hematology | Hematology Oncology
Massachusetts General Physicians Organization Inc
55 Fruit St, 
Boston, MA 
 (34.5 mi)
Clinical Trials:Currently Recruiting for 2 Trials
Accepting New Patients
Offers Telehealth
Distinguished in Lung Nodules
Massachusetts General Physicians Organization Inc
55 Fruit St, 
Boston, MA 
 (34.5 mi)
OverviewInsuranceLocationsClinical Research

Overview

Justin Gainor is an Oncologist and a Hematologist in Boston, Massachusetts. Dr. Gainor and is rated as a Distinguished provider by MediFind in the treatment of Lung Nodules. His top areas of expertise are Non-Small Cell Lung Cancer (NSCLC), Lung Cancer, Lung Adenocarcinoma, and EGFR Positive Lung Cancer. Dr. Gainor is currently accepting new patients.

His clinical research consists of co-authoring 225 peer reviewed articles and participating in 10 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 1 article in the study of Lung Nodules.

Specialties
Oncology
Hematology
Hematology Oncology
Licenses
Internal Medicine in MA
Hospital Affiliations
Martha's Vineyard Hospital Inc
Massachusetts General Hospital
Brigham And Women's Hospital
Languages Spoken
English
Gender
Male

Insurance

Please contact the provider to confirm they accept your insurance or if you don't see your insurance listed.

Accepted insurance plans

  •  Humana

Locations

MASSACHUSETTS GENERAL PHYSICIANS ORGANIZATION INC
55 Fruit St, Boston, MA 02114

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

10 Clinical Trials

A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-022, an Anti-TIM-3 Monoclonal Antibody, in Patients With Advanced Solid Tumors (AMBER)
A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-022, an Anti-TIM-3 Monoclonal Antibody, in Patients With Advanced Solid Tumors (AMBER)
Enrollment Status: Recruiting
Publish Date: June 20, 2024
Intervention Type: Drug
Study Drugs: TSR-022, Nivolumab, TSR-042, TSR-033, Docetaxel
Study Phase: Phase 1
A Screening Protocol to Determine Tumor Antigen Expression and HLA Sub-Type for Eligibility Determination for Clinical Trials Evaluating the Safety and Efficacy of Autologous T Cells Expressing Enhanced TCRs in Subjects With Solid and Hematological Malignancies
A Screening Protocol to Determine Tumor Antigen Expression and HLA Sub-Type for Eligibility Determination for Clinical Trials Evaluating the Safety and Efficacy of Autologous T Cells Expressing Enhanced TCRs in Subjects With Solid and Hematological Malignancies
Enrollment Status: Recruiting
Publish Date: August 21, 2023
A Phase I/Ib, Open-label, Multi-center, Study of DKY709 as a Single Agent and in Combination With PDR001 in Patients With Advanced Solid Tumors
A Phase I/Ib, Open-label, Multi-center, Study of DKY709 as a Single Agent and in Combination With PDR001 in Patients With Advanced Solid Tumors
Enrollment Status: Active_not_recruiting
Publish Date: February 21, 2025
Intervention Type: Drug
Study Drugs: DKY709, PDR001
Study Phase: Phase 1
Biomarkers of Response to Ipilimumab and Nivolumab as First-line Therapy for Metastatic Non-small Cell Lung Cancer (NSCLC): an Open-label, Single Arm Phase 2 Study
Biomarkers of Response to Ipilimumab and Nivolumab as First-line Therapy for Metastatic Non-small Cell Lung Cancer (NSCLC): an Open-label, Single Arm Phase 2 Study
Enrollment Status: Terminated
Publish Date: August 22, 2024
Intervention Type: Drug
Study Phase: Phase 2
A Phase II Study of Pembrolizumab in Refractory Advanced Esophageal Cancer
A Phase II Study of Pembrolizumab in Refractory Advanced Esophageal Cancer
Enrollment Status: Completed
Publish Date: September 21, 2023
Intervention Type: Drug
Study Drug: Pembrolizumab
Study Phase: Phase 2
Phase 2 Multicenter Trial of ICOS Agonist Monoclonal Antibody (mAb) Vopratelimab (JTX -2011) and a CTLA-4 Inhibitor in PD-1/PD-L1 Inhibitor Experienced Adult Subjects With Non-small Cell Lung Cancer or Urothelial Cancer
Phase 2 Multicenter Trial of ICOS Agonist Monoclonal Antibody (mAb) Vopratelimab (JTX -2011) and a CTLA-4 Inhibitor in PD-1/PD-L1 Inhibitor Experienced Adult Subjects With Non-small Cell Lung Cancer or Urothelial Cancer
Enrollment Status: Completed
Publish Date: September 10, 2022
Intervention Type: Drug
Study Drugs: Vopratelimab, Ipilimumab
Study Phase: Phase 2
Open Label Multicenter Phase I/II Study of the Safety and Efficacy of PDR001 Administered to Patients With Advanced Malignancies
Open Label Multicenter Phase I/II Study of the Safety and Efficacy of PDR001 Administered to Patients With Advanced Malignancies
Enrollment Status: Completed
Publish Date: August 03, 2022
Intervention Type: Biological
Study Phase: Phase 1/Phase 2
A Phase 1b/2 Study of ARRY-382 in Combination With Pembrolizumab, a Programmed Cell Death Receptor 1 (PD-1) Antibody, for the Treatment of Patients With Advanced Solid Tumors
A Phase 1b/2 Study of ARRY-382 in Combination With Pembrolizumab, a Programmed Cell Death Receptor 1 (PD-1) Antibody, for the Treatment of Patients With Advanced Solid Tumors
Enrollment Status: Terminated
Publish Date: June 16, 2022
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
A Pilot Open-Label Clinical Trial Evaluating the Safety and Efficacy of Autologous T Cells Expressing Enhanced TCRs Specific for NY-ESO-1 in Subjects With Stage IIIb or Stage IV Non-Small Cell Lung Cancer (NSCLC)
A Pilot Open-Label Clinical Trial Evaluating the Safety and Efficacy of Autologous T Cells Expressing Enhanced TCRs Specific for NY-ESO-1 in Subjects With Stage IIIb or Stage IV Non-Small Cell Lung Cancer (NSCLC)
Enrollment Status: Completed
Publish Date: September 05, 2021
Intervention Type: Drug
Study Phase: Phase 1
A Phase I Dose Escalation Open Label Clinical Trial Evaluating the Safety and Efficacy of MAGE A10ᶜ⁷⁹⁶T in Subjects With Stage IIIb or Stage IV Non-Small Cell Lung Cancer (NSCLC)
A Phase I Dose Escalation Open Label Clinical Trial Evaluating the Safety and Efficacy of MAGE A10ᶜ⁷⁹⁶T in Subjects With Stage IIIb or Stage IV Non-Small Cell Lung Cancer (NSCLC)
Enrollment Status: Completed
Publish Date: April 09, 2021
Intervention Type: Biological
Study Phase: Phase 1
View 8 Less Clinical Trials

225 Total Publications

Spatial biology captures the effects of neoadjuvant chemo-immunotherapy in lung cancer.
Spatial biology captures the effects of neoadjuvant chemo-immunotherapy in lung cancer.
Journal: Nature genetics
Published: December 10, 2024
Similar Doctors
Advanced in Lung Nodules
Dr. Jennifer S. Temel
Oncology | Hematology
Advanced in Lung Nodules
Dr. Jennifer S. Temel
Oncology | Hematology

Massachusetts General Physicians Organization Inc

55 Fruit St, 
Boston, MA 
617-724-0287
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Jennifer Temel is an Oncologist and a Hematologist in Boston, Massachusetts. Dr. Temel and is rated as an Elite provider by MediFind in the treatment of Lung Nodules. Her top areas of expertise are Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), EGFR Positive Lung Cancer, Bone Marrow Transplant, and Gastrostomy. Dr. Temel is currently accepting new patients.

Distinguished in Lung Nodules
Dr. Paresh P. Mane
Thoracic Surgery | General Surgery | Oncology
Distinguished in Lung Nodules
Dr. Paresh P. Mane
Thoracic Surgery | General Surgery | Oncology
4 Inwood Ln, 
Andover, MA 
 (23.1 mi)
857-939-0475
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Paresh Mane is a Thoracic Surgeon and a General Surgeon in Andover, Massachusetts. Dr. Mane and is rated as a Distinguished provider by MediFind in the treatment of Lung Nodules. His top areas of expertise are Lung Nodules, Pleuropulmonary Blastoma, Squamous Cell Lung Carcinoma, Gastrostomy, and Endoscopy. Dr. Mane is currently accepting new patients.

Ibiayi Dagogo-Jack
Advanced in Lung Nodules
Dr. Ibiayi Dagogo-Jack
Hematology Oncology | Hematology | Oncology
Advanced in Lung Nodules
Dr. Ibiayi Dagogo-Jack
Hematology Oncology | Hematology | Oncology

The General Hospital Corporation

55 Fruit St, 
Boston, MA 
617-726-2000
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Ibiayi Dagogo-Jack is a Hematologist Oncology specialist and a Hematologist in Boston, Massachusetts. Dr. Dagogo-Jack and is rated as an Elite provider by MediFind in the treatment of Lung Nodules. Her top areas of expertise are Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), Lung Adenocarcinoma, Mesothelioma, and Tissue Biopsy. Dr. Dagogo-Jack is currently accepting new patients.

Areas of Expertise

When evaluating expertise, MediFind pulls from factors such as the number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

To learn more about how MediFind determines the expertise levels, check out our expert tiers page.

Search for your specific condition
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile